| dc.contributor.author | Schutte, Aletta E. | |
| dc.date.accessioned | 2019-10-29T08:27:14Z | |
| dc.date.available | 2019-10-29T08:27:14Z | |
| dc.date.issued | 2019 | |
| dc.identifier.citation | Schutte, A.E. 2019. A call for improved reporting on serious adverse events in clinical trials. Journal of hypertension, 37(11):2154-2155. [https://doi.org/10.1097/HJH.0000000000002194] | en_US |
| dc.identifier.issn | 0263-6352 | |
| dc.identifier.issn | 1473-5598 (Online) | |
| dc.identifier.uri | http://hdl.handle.net/10394/33501 | |
| dc.identifier.uri | https://journals.lww.com/jhypertension/Fulltext/2019/11000/A_call_for_improved_reporting_on_serious_adverse.6.aspx | |
| dc.identifier.uri | https://doi.org/10.1097/HJH.0000000000002194 | |
| dc.description.abstract | Following SPRINT (Systolic Blood Pressure Intervention Trial) [1], several investigations including systematic reviews and meta-analyses confirmed that reducing SBP to levels below 140 mmHg markedly reduces the risk of cardiovascular disease and all-cause mortality. In a recent systematic review, Bundy et al. [2] included 42 trials (including 144 220 patients) and showed that randomized groups with a mean achieved SBP of 120–124 mmHg had a hazard ratio for major cardiovascular disease of 0.71 (95% confidence interval 0.60–0.83) compared with groups with a mean achieved SBP of 130–134 mmHg; a hazard ratio of 0.58 compared with those with an achieved SBP of 140–144 mmHg; and a hazard ratio of 0.36 compared with those with a mean achieved SBP of at least 160 mmHg. Similar findings were reported for all-cause mortality. These and other reports call for more intensive control of SBP among adults with hypertension | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Wolters Kluwer | en_US |
| dc.title | A call for improved reporting on serious adverse events in clinical trials | en_US |
| dc.type | Article | en_US |
| dc.contributor.researchID | 10922180 - Schutte, Aletta Elisabeth | |
